Cardiac MRI ECV Persistence Score (Post-Viral Fibrosis Risk) Calculator

Clinical calculation support · Verify results before clinical use

Enter CMR parameters

Enter baseline and follow-up measurements. Use the same scanner and protocol when feasible, and compare values with local reference ranges.

0–13Score range
Percent, not a fraction. Verify against the site's sequence-specific reference range.
Prefer comparable scanner, field strength, sequence, and analysis method.
Interval from baseline to follow-up CMR.
Enter 0 if no LGE is reported. If presence and extent conflict, verify the report.
Clear form
Experimental tool: the scoring weights, cutoffs, and score bands below have not been established as a validated clinical prediction model. The output is not a probability, does not diagnose fibrosis, and must not independently determine treatment or follow-up.

Clinical context and limitations

CMR tissue-characterization parameters can support assessment of myocardial injury and extracellular expansion. ECV is not specific for collagen fibrosis: edema and other processes can also increase extracellular space. Native T1 and ECV values depend on acquisition and analysis methods and should be interpreted using local, sequence-specific reference values.

How to interpret this calculator

  • The point weights and score bands are inherited from the supplied experimental code; they have not been validated as a prediction rule in a defined post-viral myocarditis cohort.
  • A follow-up interval under 3 months receives zero persistence points in the original algorithm, but this is not evidence that fibrosis has resolved.
  • LGE pattern, location, extent, ventricular function, edema markers, clinical status, and alternative diagnoses remain important to expert interpretation.
  • Do not use the score alone to determine treatment, exercise restriction, return to sport, or timing of repeat CMR.

Scoring rules retained from the source code

ComponentOriginal experimental rule
Baseline ECV<28%: 0; 28–<30%: 1; 30–<33%: 2; 33–<35%: 3; ≥35%: 4
Follow-up ECV (≥3 months)<30%: 0; 30–<33%: 2; 33–<35%: 3; ≥35%: 4
LGEAbsent: 0; present and <10%: 2; 10–<15%: 3; ≥15%: 4
Native T1Elevated: 1; normal/unknown: 0

References

Messroghli DR, Moon JC, Ferreira VM, et al.

Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the SCMR endorsed by the EACVI. J Cardiovasc Magn Reson. 2017;19:75.

doi:10.1186/s12968-017-0389-8
Ferreira VM, Schulz-Menger J, Holmvang G, et al.

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018;72(24):3158–3176.

doi:10.1016/j.jacc.2018.09.072
Clinical disclaimer: This calculator is for education and decision support only. It is an unvalidated experimental score and has no established sensitivity, specificity, calibration, or outcome-based risk thresholds. CMR results should be interpreted by appropriately trained clinicians in the context of the full clinical assessment and local imaging protocols.